Introduction: The German Research Activities on Natural Urologicals (GRANU) study was a randomized, partially blinded, placebo-controlled, parallel-group trial that investigated the efficacy of pumpkin seed in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH/LUTS). Subjects and Methods: A total of 1,431 men (50−80 years) with BPH/LUTS were randomly assigned to either pumpkin seed (5 g b.i.d.), capsules with pumpkin seed extract (500 mg b.i.d.) or matching placebo. The primary response criterion was a decrease in International Prostate Symptom Score (IPSS) of ≥5 points from baseline after 12 months. Secondary outcome measures included IPSS-related quality of life, IPSS single items and diary-recorded nocturia. Results: After 12 months, the response rate (intention-to-treat/last-observation-carried-forward approach) did not differ between pumpkin seed extract and placebo. In the case of pumpkin seed (responders: 58.5%), the difference compared with placebo (responders: 47.3%) was descriptively significant. The study products were well tolerated. Overall, in men with BPH, 12 months of treatment with pumpkin seed led to a clinically relevant reduction in IPSS compared with placebo. Conclusion: In order to fully justify a recommendation for the use of pumpkin seed to treat moderate LUTS, these findings need to be substantiated in a confirmatory study or systematic review.

Journal Section:
Editor's choice
Keywords:
Benign prostatic hyperplasia, <italic>Cucurbita pepo</italic>, International Prostate Symptom Score, Lower urinary tract symptoms, Pumpkin seed, Quality of life
1.
German Commission E: Cucurbitae peponis semen. Bundesanzeiger No 223, Nov 30, 1985, correction Bundesanzeiger No 11, Jan 17, 1991.
2.
Pater B: Über die Heilkraft des Kürbissamens. Heil Gewürzpfl 1929;12:18-20.
3.
Committee on Herbal Medicinal Products (HMPC): Assessment report on Cucurbita pepo L., semen. EMA/HMPC/136022/2010, Nov 20, 2012, fist published March 25, 2013.
4.
Nitsch-Fitz R, Egger H, Wutzl H, Maruna H: Einsatz des Kürbiskern-Diätetikums ‘Kürbis-Granufink' bei Patienten mit Prostatahypertrophie in Wiener Allgemeinpraxen. Erfahrungsheilkunde 1979;28:1009-1013.
5.
Nitsch-Fitz R, Egger H, Wutzl H, Maruna H: Ergebnisse einer Praxisstudie über das Kürbiskern-Diätetikum ‘Kürbis-Granufink' bei Patienten mit Miktionsbeschwerden verschiedener Genese. Dr Med 1979;3:38-40.
6.
Strobl M, Patz B, Bracher F: Kürbissamen bei Störungen der Blasenfunktion. DAZ 2004;144:4010-4014.
7.
Bracher F, Plössl F: Identification and determination of phytosterols in pharmaceutical preparations. Annu Meet DPhG (Deutsche Pharmazeutische Gesellschaft), Jena, 2009.
https://doi.org/10.1055/s-0029-1239896
8.
Abdel-Rahman MK: Effect of pumpkin seed (Cucurbita pepo L.) diets on benign prostatic hyperplasia (BPH): chemical and morphometric evaluation in rats. World J Chem 2006,1:33-40.
9.
Gossell-Williams M, Davis A, O'Connor N: Inhibition of testosterone-induced hyperplasia of the prostate of Sprague-Dawley rats by pumpkin seed oil. J Med Food 2006;9:284-286.
[PubMed]
https://doi.org/10.1089/jmf.2006.9.284
10.
Tsai YS, Tong YC, Cheng JT, Lee CH, Yang FS, Lee HY: Pumpkin seed oil and phytosterol-F can block testosterone/prazosin-induced prostate growth in rats. Urol Int 2006;77:269-274.
[PubMed]
https://doi.org/10.1159/000094821
11.
Zhang X, Ouyang J, Zhang Y, Tayalla B, Zhou X, Zhou S: Effect of the extracts of pumpkin seeds on the urodynamics of rabbits: an experimental study. J Tongji Med Univ 1994;14:235-238.
[PubMed]
https://doi.org/10.1007/BF02897676
12.
Kim SH, Jung KI, Koh JS, Min KO, Cho SY, Kim HW: Lower urinary tract symptoms in benign prostatic hyperplasia patients: orchestrated by chronic prostatic inflammation and prostatic calculi? Urol Int 2013;90:144-149.
[PubMed]
https://doi.org/10.1159/000342643
13.
Fahim AT, Abd-El-Fattah AA, Agha AM, Gad MZ: Effect of pumpkin-seed oil on the level of free radical scavengers induced during adjuvant-arthritis in rats. Pharmacol Res 1995;31:73-79.
[PubMed]
https://doi.org/10.1016/1043-6618(95)80051-4
14.
Denis L, McConnell JD, Yoshica O, Khoury S, Abrams P, Barry M, et al: Recommendations of the International Scientific Committee: the evaluation and treatment of lower urinary tract syndromes (LUTS) suggestive of benign prostatic obstruction; in Denis L, Griffiths K, Khoury S, et al (eds): Proceedings of the 4th International Consultation on Benign Prostatic Hyperplasia (BPH). Plymouth, Plymbridge, 1998, pp 669-683.
15.
Bach D: Placebokontrollierte Langzeitstudie mit Kürbissamenextrakt bei BPH-bedingten Miktionsbeschwerden. Urologe B 2000;40:437-443; erratum in Urologe B 2001;41:42.
https://doi.org/10.1007/s001310050432
16.
Madersbacher S, Marszalek M, Lackner J, Berger P, Schatzl G: The long-term outcome of medical therapy for BPH. Eur Urol 2007;51:1522-1533.
[PubMed]
https://doi.org/10.1016/j.eururo.2007.03.034
17.
MacDonald R, Tacklind JW, Rutks I, Wilt TJ: Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review. BJU Int 2012;109:1756-1761.
[PubMed]
https://doi.org/10.1111/j.1464-410X.2012.11172.x
18.
Adey GS, O'Leary MP, Barry MJ: Evaluating symptoms and functional status; in Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P (eds): Textbook of Benign Prostatic Hyperplasia. London, Tayler & Francis, 2005, pp 201-209.
19.
Dong Y, Hao L, Shi Z, Wang G, Zhang Z, Han C: Efficacy and safety of tadalafil monotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a meta-analysis. Urol Int 2013;91:10-18.
[PubMed]
https://doi.org/10.1159/000351405
20.
Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N'Dow J, Nordling J, de la Rosette JJ: EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2013;64:118-140.
[PubMed]
https://doi.org/10.1016/j.eururo.2013.03.004
21.
Madersbacher S, Ponholzer A, Berger I, Marszalek M: Medical management of BPH: role of plant extracts. EAU EBU Update Ser 2007;5:197-205.
https://doi.org/10.1016/j.eeus.2007.04.004
22.
Hutchison A, Farmer R, Verhamme K, Berges R, Navarrete RV: The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. Eur Urol 2007;51:207-215.
[PubMed]
https://doi.org/10.1016/j.eururo.2006.06.012
23.
Schneider T, Ruebben H: Stinging nettle root extract (Bazoton uno) in long term treatment of benign prostatic syndrome (BPS). Results of a randomized, double-blind, placebo-controlled multicenter study after 12 months (in German). Urologe A 2004;43:302-306.
[PubMed]
https://doi.org/10.1007/s00120-004-0532-7
24.
Homma Y, Kawabe K, Tsukamoto T, Tsukamoto R. Yamaguchi O, Okada K, Aso Y, Watanabe H, Okajima E, Kumazawa J, Yamaguchi T, Ohashi Y: Estimate criteria for efficacy of treatment in benign prostatic hyperplasia. Int J Urol 1996;3:267-273.
[PubMed]
https://doi.org/10.1111/j.1442-2042.1996.tb00532.x
25.
Konstantinidis C, Samainas M, Andreadakis S, Xanthis S, Skriapas K: Lower urinary tract symptoms associated with benign prostatic hyperplasia: combined treatment with fesoterodine fumarate extended-release and tamsulosin - a prospective study. Urol Int 2013;90:156-160.
[PubMed]
https://doi.org/10.1159/000345050
26.
Săglam HS, Görkaya CS, Salar R, Memiş A, Adsan Ö: The effects of age, metabolic syndrome, nocturnal polyuria and sleep disorders on nocturia. Adv Clin Exp Med 2013;22:489-494.
[PubMed]
27.
O'Leary MP: Validity of the ‘bother score' in the evaluation and treatment of symptomatic benign prostatic hyperplasia. Rev Urol 2005;7:1-10.
[PubMed]
© 2014 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2014
You do not currently have access to this content.